Choosing an anticoagulant comes down to a few axes: what it inhibits (thrombin vs factor Xa vs vitamin-K-dependent synthesis), how fast it turns on and off (half-life), how much depends on the kidney, whether it needs monitoring, and whether it can be reversed. The renal-clearance column is the one most likely to change a decision in CKD — dabigatran is the most renally cleared (80%); apixaban the least (27%).

Scroll sideways to view all columns.

Scroll sideways to view all columns.

First branch point is always life-threatening vs not. For non-major bleeding: hold the drug, apply local hemostasis, support — most anticoagulants clear on their own given their half-lives. Reverse only for life-threatening or critical-site bleeding (intracranial, intraspinal, pericardial, airway) or an emergent procedure. Always loop in pharmacy and the relevant specialist.

Warfarin — Vitamin K (IV for urgent reversal) plus 4F-PCC (KCentra) for severe bleeding or emergent procedure; vitamin K is always co-given because PCC factors are short-lived while warfarin's effect persists.

Factor Xa inhibitors (apixaban / rivaroxaban / edoxaban) — for severe/life-threatening bleeding with clinically significant anticoagulant effect, 4F-PCC 2,000 units IV once is an off-label U.S. guideline option. FDA concluded Andexxa's risks outweigh its benefits; U.S. commercial sales ended December 22, 2025.

Dabigatran — Idarucizumab (Praxbind) 5 g IV as two consecutive 2.5-g vials is the specific labeled antidote. If unavailable and urgent reversal is required: PCC or activated PCC 50 units/kg IV once (max 4,000 units) is an off-label U.S. guideline fallback. Limited labeling data show about 49% dialysis removal over 4 hours at 200 mL/min blood flow, followed by redistribution.

UFH / LMWH — Protamine is given slowly, with no more than 50 mg over any 10-minute period. It neutralizes UFH, but enoxaparin anti-factor-Xa activity is never completely neutralized (maximum about 60%). Fondaparinux has no specific reversal agent — use specialist-directed supportive and hemostatic management for life-threatening bleeding.

KCENTRA and HIT: KCENTRA contains heparin and is contraindicated in patients with known HIT. Its labeling does not provide an exception based on elapsed time or negative HIT antibody testing. If urgent reversal is required in a patient with a HIT history, obtain an individualized plan from the treating team, including hematology and the anticoagulation team, following the institutional reversal protocol.

Remote HIT is a separate question. HIT antibodies often become undetectable over time. Selected heparin re-exposure in planned cardiac/vascular procedures requires assessment of platelet recovery, antibody/functional testing and the procedural context. That evidence does not grant KCENTRA clearance.

Alternative reversal is specialist-directed. FEIBA/activated PCC, other concentrates, adjuncts or plasma are not automatic substitutes merely because a product is heparin-free. Selection must account for the anticoagulant, bleeding site and severity, urgency, product ingredients and thrombotic risk. No automatic FEIBA, 3F-PCC/factor-VII combination or other alternative regimen is supplied here. Warfarin reversal still requires vitamin K as clinically indicated.

Platelets: give them for genuine thrombocytopenia or before neurosurgery — but don't reflexively transfuse for spontaneous antiplatelet-associated ICH. The PATCH trial found platelet transfusion worsened death/dependence (adjusted OR ~2). Calcium: blood products are citrated, and citrate chelates calcium (and magnesium). Large-volume FFP/platelet/PRBC transfusion drops ionized calcium — and calcium (factor IV) is required for the clotting cascade and platelet function, so hypocalcemia is itself a coagulopathy. Check ionized calcium and replace it (calcium gluconate or chloride) during massive transfusion.

DOACs are designed not to need routine monitoring — fixed dosing, predictable PK. Levels matter only in edge cases (bleeding, urgent surgery, extremes of weight, renal failure, suspected non-adherence) and require drug-specific, calibrated assays, not PT/aPTT.

Scroll sideways to view all columns.

The anti-Xa assay is chromogenic — the lab adds a fixed amount of factor Xa plus a substrate that turns the sample a color when Xa cleaves it. Heparin (through antithrombin) inhibits some of that Xa, so less color = more heparin, read off a curve calibrated to heparin. The catch: a direct Xa inhibitor (apixaban, rivaroxaban, edoxaban) also inhibits that Xa and dims the color — but the analyzer can't tell which drug did it, so it attributes the whole effect to heparin → a falsely high heparin anti-Xa. The apparent heparin level may overstate UFH activity. The duration and degree of interference depend on the assay, drug exposure, renal function and interacting drugs; do not assume a universal clearance interval.

Practical move: if the patient was recently on a Xa-inhibitor DOAC, draw a baseline anti-Xa before starting heparin. An elevated result may reflect residual drug or other factors. Obtain laboratory and anticoagulation-team input; use the institutional transition and monitoring protocol, including aPTT when appropriate. Both assays have limitations.

Second trap: many anti-Xa reagents add exogenous antithrombin, which can mask antithrombin-deficiency heparin resistance — the level reads therapeutic while the patient is actually under-anticoagulated. Suspect it when infusion rates run very high (> 25–30 units/kg/hr) against a flat aPTT.

What it is: heparin-induced thrombocytopenia is an immune reaction — antibodies against the heparin–platelet factor 4 (PF4) complex bind and activate platelets via their Fc receptors, driving a prothrombotic state. Counterintuitively, the danger is thrombosis (arterial or venous), not bleeding, despite the falling platelet count.

Timing: platelets typically fall 5–10 days after heparin starts, or within ~1 day if there was heparin exposure in the prior ~100 days (anamnestic). Far more common with UFH than LMWH.

4T logic: the score weighs Thrombocytopenia magnitude, Timing, Thrombosis/sequelae, and whether oTher causes exist. Low score (≤3) has a high negative predictive value — pursue other causes before committing to a HIT workup. Use the 4T calculator in the Heparin/DTI tab.

What to do: stop all heparin sources (flushes, line locks, LMWH) and start a non-heparin anticoagulant — a direct thrombin inhibitor (argatroban, bivalirudin), fondaparinux, or a DOAC (off-label). Avoid prophylactic platelet transfusions. Premature warfarin can cause venous limb gangrene. When warfarin is selected for HIT, begin after platelet recovery, usually ≥150 × 10⁹/L. Overlap with the non-heparin anticoagulant for at least 5 days AND until the intended INR target is reached, accounting for argatroban interference. Monitor INR daily during overlap. At argatroban ≤2 mcg/kg/min, after these overlap conditions are met, the label permits stopping when the combined INR is >4. At >2 mcg/kg/min, first reduce to 2 and repeat INR 4–6 hours later, then apply that method. After stopping, repeat INR in 4–6 hours. If below the intended therapeutic range, restart argatroban and repeat the process daily until the warfarin-alone INR meets the target. Coordinate this transition with the treating team, including the anticoagulation/hematology team, using the applicable institutional protocol. Send a PF4 ELISA, confirm with a functional assay (SRA).

Sick / unstable, bleeding risk, or a procedure may be needed → DTI infusion. Argatroban or bivalirudin are IV, titratable, and clear fast, so you can turn them off. Argatroban for renal failure (hepatic clearance); bivalirudin if hepatic impairment or short offset is the priority.

Clinically stable, average bleed risk, no limb/life-threatening clot → fondaparinux or a DOAC. Once-daily SC (fonda) or oral, no routine monitoring, outpatient-friendly. The trade-off is a long offset and no reversal — fondaparinux is off-label for HIT and contraindicated in severe renal failure (renally cleared). Avoid it in unstable patients, with high bleeding risk or an imminent procedure; involve hematology/anticoagulation specialists. CrCl <30 mL/min is contraindicated. Weight <50 kg is a contraindication for adult surgical prophylaxis, whereas adult DVT/PE treatment is labeled at 5 mg SC once daily below 50 kg. HIT treatment remains off-label and requires careful patient selection; low weight increases bleeding risk.

Bridging is mostly a warfarin question. DOACs have short half-lives, so the drug clears on its own during a brief hold — bridging is not needed. For warfarin, consider bridging only after individualized assessment of thromboembolic risk, bleeding risk and procedure-specific exceptions with the treating and anticoagulation teams. BRIDGE studied perioperative AF interruption, not acute-VTE treatment or routine warfarin initiation; it excluded mechanical valves and recent stroke/TIA/systemic embolism.

DOAC hold by bleed risk + renal function: minimal-bleed-risk procedures generally don't require interruption; high-bleed-risk procedures hold ≥ 2 days (4–5 half-lives), longer for dabigatran as CrCl falls. Use the Periop tab's hold calendar for exact dates.

Scroll sideways to view all columns.

A measured drug level under ~30 ng/mL can permit earlier neuraxial placement when timing is unavoidable. Coordinate with the proceduralist and anesthesiology.

Adult conversion teaching: confirm the indication, renal function, current dose, last administration, bleeding risk and intended anticoagulation target with the anticoagulation team. Prevent unintended gaps or excessive overlap; these instructions do not select a new drug or dose. Acute DVT/PE treatment with dabigatran or edoxaban requires 5–10 days of initial parenteral anticoagulation and appropriate renal eligibility.

Scroll sideways to view all columns.

Warfarin has a delayed effect. Existing clotting factors must clear, and protein C/S can fall early. The appropriate overlap depends on the indication and starting drug. Acute VTE treatment and routine warfarin initiation are separate from perioperative interruption; the BRIDGE trial does not establish their overlap rules.

BRIDGE evidence: In the studied perioperative AF population, omitting LMWH bridging was noninferior for arterial thromboembolism and caused less major bleeding. Mechanical valves and recent stroke/systemic embolism/TIA were excluded; few patients had the highest stroke-risk scores. Do not generalize this result to acute VTE treatment, routine initiation or every high-risk patient.

INR interference matters. A combined INR can include the DOAC’s effect. Use the specific transition method and sampling time above; a universal “keep every DOAC running while warfarin loads” instruction is inappropriate. Alternative guideline or local protocols must be explicitly identified and reviewed with the anticoagulation team.

Vitamin K only fixes a problem caused by lack of vitamin K. Give it for warfarin reversal, or for a true deficiency — not reflexively for every high INR. The trap in the hospital is giving it for an elevated INR that is actually liver synthetic failure, where it does nothing.

Suspect vitamin K deficiency when the INR is up and the patient has a reason to be depleted: NPO / poor intake for several days, malnutrition (common in long-stay ICU), prolonged antibiotics (wipe out gut flora that make vitamin K), or fat malabsorption / cholestasis (celiac, short gut, CF, biliary obstruction, bariatric). Vitamin K is fat-soluble, so anything blocking fat absorption blocks it. You usually don't need a level — the risk-factor history and a vitamin-K-responsive INR support the assessment, but do not independently establish the diagnosis.

Factor V. The liver produces it, but it is not vitamin-K-dependent. Preserved factor V with reduced vitamin-K-dependent factors can support vitamin K deficiency or vitamin K antagonist effect. Reduced factor V can support impaired liver synthesis, but consumption (including DIC) and a factor V inhibitor are other possibilities. Factor V alone does not establish the cause. Albumin, bilirubin, the broader coagulation pattern and clinical history provide additional context.

Response to vitamin K is a clue. INR improvement supports a vitamin-K-responsive component, including deficiency or antagonist effect. Interpret the response according to the dose, elapsed time, route and absorption, medication exposure and the clinical situation. An absent or incomplete response is not proof of hepatic failure: reassess those factors and investigate alternative or mixed causes. When findings conflict or the cause remains unclear, involve hematology and the treating team, with hepatology or anticoagulation specialists as appropriate.

In cirrhosis, most elevated INRs are not vitamin K deficiency — so don't chase the number. The diseased liver runs a "rebalanced" hemostasis: it makes less of both the pro-coagulant and the anticoagulant factors, so a high INR mostly reflects disease severity (it's a MELD input) rather than net bleeding risk. Routine or repeated high-dose phytonadione barely moves the INR and doesn't reduce bleeding. Reserve it for a genuine deficiency reason (cholestasis, malnutrition, prolonged antibiotics) or actual warfarin reversal.

2.5–10 mg covers almost everything — higher doses rarely reverse any faster, and > 10 mg saturates hepatic stores → warfarin resistance for days to ~a week (you'll struggle to re-anticoagulate). Match route to urgency: oral is reliable when you can wait; IV is fastest (measurable INR drop within a few hours) but carries a small anaphylactoid risk, so give it diluted and slow as an IVPB, never a push. Skip SC and IM — subcutaneous absorption is erratic and IM risks a hematoma in an anticoagulated patient. All routes reach full effect by ~24 h.

Most medical inpatients with reduced mobility get pharmacologic prophylaxis unless bleeding risk is high. Default is enoxaparin 40 mg SC daily (or 30 mg q12h in trauma/ortho), UFH 5,000 units SC q8–12h when renal function is poor (CrCl < 30) or rapid reversibility matters, or fondaparinux if HIT history. Mechanical (SCDs) when anticoagulation is contraindicated. Prophylaxis doses are fixed and low — they are not treatment doses and don't need monitoring.

Different problem: antiplatelets target arterial, platelet-rich clot (coronary, cerebrovascular, peripheral), anticoagulants target venous/stasis, fibrin-rich clot (VTE, AF cardioembolism). They are not interchangeable, and combining them multiplies bleeding risk — only do it with a clear indication and a planned duration.

Scroll sideways to view all columns.

Aspirin + a P2Y12 inhibitor after ACS or stent — typically ~12 months, shortened when bleeding risk is high, extended when ischemic risk dominates. Ticagrelor or prasugrel are preferred over clopidogrel in ACS; clopidogrel is preferred for stable/elective PCI. If the patient also needs an OAC (e.g. AF + stent): drop aspirin early (often by discharge) and run OAC + clopidogrel — triple therapy only briefly, because stacking three agents bleeds.

These are therapeutic (treatment) doses — distinct from the fixed low prophylaxis doses. In the US the two agents you'll actually reach for are enoxaparin (the default) and dalteparin (cancer VTE); tinzaparin isn't marketed here.

Scroll sideways to view all columns.

Enoxaparin is renally cleared, so it accumulates and bleeds when kidneys fail. At CrCl < 30, reduce treatment dosing to 1 mg/kg once daily and consider anti-Xa monitoring — or, often better, switch to a UFH infusion (not renally cleared, fully reversible; one QI series cut major bleeding from ~13% to ~4% doing exactly this). Dalteparin bioaccumulates less and is the more defensible LMWH if you must use one in renal impairment or the elderly. Fondaparinux is a hard stop below CrCl 30.

Enoxaparin — default for VTE, ACS, and warfarin/DOAC bridging: familiar, stocked everywhere, flexible (q12h or daily). Dalteparin — cancer-associated VTE (the CLOT weight-based regimen) and a reasonable renal/elderly choice. Fondaparinux — when you need a HIT-safe, no-monitoring, once-daily agent and renal function is fine. UFH infusion — severe renal failure, high bleeding risk, or when a procedure may be imminent (rapid off, reversible).

DOACs (apixaban, edoxaban, rivaroxaban) are now first-line for most cancer-associated VTE. Keep LMWH (dalteparin) when there's a luminal GI or GU cancer (DOACs — especially edoxaban/rivaroxaban — bleed more there), significant thrombocytopenia, vomiting/absorption problems, or major drug interactions with anticancer therapy.

Most patients need none. Check a peak anti-Xa 4 h after the 3rd–4th dose in the edge cases: severe renal impairment on prolonged therapy, extremes of weight, and pregnancy. Rough peaks — q12h dosing ~0.6–1.0 IU/mL, once-daily >1.0. (Dose adjustment or switching agents may be preferred over routine monitoring, since levels are often slow to come back.)